Delayed presentation of biopsy-proven eosinophilic myocarditis following COVID-19 mRNA vaccine

3Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

Myopericarditis associated with COVID-19 mRNA vaccines has been recognized as an uncommon adverse reaction, especially among young, healthy adult males. Eosinophilic myocarditis is a rare form of inflammation reflecting a hypersensitivity reaction following an inciting event commonly caused by drugs including vaccines. Eosinophilic myocarditis, a subtype of myocarditis, is characterized by eosinophilic myocardial infiltrates. It is usually accompanied by systemic eosinophilia in the form of a drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome and is rarely associated with myocyte fibrosis and/or necrosis. In this report, we present a case of biopsy-proven eosinophilic myocarditis in a 24-year-old male patient, likely secondary to COVID-19 mRNA vaccination. To our knowledge, this is the first report to describe delayed eosinophilic myocarditis following the COVID-19 mRNA vaccine. Clinicians should be aware of possible delayed presentation to avoid associated morbidity.

Cite

CITATION STYLE

APA

Janga, C., Patel, T., Al Hennawi, H., Atam, S., Shah, S., Naeem, I., … Haas, D. C. (2023). Delayed presentation of biopsy-proven eosinophilic myocarditis following COVID-19 mRNA vaccine. Global Cardiology Science and Practice, 2023(2). https://doi.org/10.21542/gcsp.2023.10

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free